期刊
PULMONARY CIRCULATION
卷 12, 期 2, 页码 -出版社
WILEY
DOI: 10.1002/pul2.12092
关键词
ascites; epoprostenol; pulmonary hypertension
The development of ascites in pulmonary arterial hypertension (PAH), without pre-existing hepatic dysfunction, is usually linked to decompensated right heart failure or cardiac cirrhosis. Ascites in PAH rarely occurs as a result of intravenous epoprostenol administration, a synthetic prostaglandin PGI(2).
The development of ascites in pulmonary arterial hypertension (PAH) in the absence of pre-existing hepatic dysfunction is usually associated with decompensated right heart failure or cardiac cirrhosis. Ascites in PAH has rarely been associated with intravenous epoprostenol, a synthetic form of the prostaglandin PGI(2).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据